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Introduction
Hemangioblastoma represents a rare tumor of the central 
nervous system (CNS) occurring both as sporadic disease and, 
especially in case of a spinal manifestation, in association with 
von Hippel-Lindau (VHL) disease [1]. The tumor cell of ori-
gin and the histogenesis of this entity remain controversial. 
The disease-associated inactivation of the VHL tumor sup-
pressor gene leads to a stabilization of the hypoxia-inducible 
factor (HIF)-1a protein and thereby to an up-regulation of 
 associated target genes, including the gene coding for the 
 vascular endothelial growth factor (VEGF) [2]. Hemangio-
blastomas are mostly encountered in the cerebellum and 
 dorsal spinal cord, where they are usually superficial, centered 
on the pial surface and well circumscribed. 2 histopathologic 
subtypes related to tumor size are recognized, including the 
smaller ‘reticular or mesenchymal type’ with a high ratio of 
vessels to tumor cells and the less common ‘cellular type’ com-
posed of large lobules of uniform cells surrounded by prolifer-
ating vessels [3]. In addition, the constituent tumor (stromal) 
cells of the reticular variant often show abundant vacuolated 
cytoplasm and are embedded in a dense reticulin network. 
The cellular variant shows less cytoplasmic vacuolation, sparse 
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Summary
Background: Antiangiogenic treatment has been explo-
red in few patients with hemangioblastoma after failure 
of surgery and radiotherapy. Case Report: We present 
the first histopathological follow-up study of a bevaci-
zumab-responsive hemangioblastoma that eventually 
progressed. For a period of 12 months, therapy with bev-
acizumab achieved a clinical response and radiological 
stabilization in a patient with progressive multifocal 
 central nervous system (CNS) hemangioblastoma. Sub-
sequently, selected tumor sites showed radiological pro-
gression, in particular, the formation of an intramedul-
lary lesion of the initially predominantly leptomeningeal 
disease. Histology showed diffuse dural invasion by the 
hemangioblastoma accompanied with a relatively re-
duced cell density compared to the preserved vessel 
structures. Conclusion: The pattern of progression upon 
vascular endothelial growth factor (VEGF)-targeting 
 antiangiogenic treatment in hemangioblastoma may 
 involve increased tumor invasiveness.
Established Facts
– Based on previous case studies, antiangiogenic treatment with bevacizumab represents a therapeutic 
option in patients with progressive and heavily pretreated hemangioblastoma.
Novel Insights
– This is the first study presenting the patterns of progression in a patient with multifocal hemangio-
blastoma after prolonged response to bevacizumab.
– Radiological and histopathological findings point towards an increased tumor invasiveness on the 
basis of relatively reduced tumor cell density in contrast to a preserved vasculature.
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pericellular reticulin and, in some cases, glioma-like fibrillar 
areas. Since VEGF and VEGF receptors (VEGFRs) are ex-
pressed in hemangioblastoma [4, 5], antiangiogenic therapy is 
now being considered as a therapeutic option beyond surgery 
and radiotherapy. To date, few cases of progressive hemangio-
blastoma treated successfully with the VEGF antibody beva-
cizumab have been published [6, 7]. In a single-arm phase II 
study with the VEGFR inhibitor sunitinib in patients with 
VHL disease, stable disease was reported in 9/11 patients with 
hemangioblastoma while 6/18 patients with other VHL-re-
lated lesions showed a partial response [8]. To better under-
stand the patterns of response and therapeutic  alterations, 
 tissue analyses of patients before and after anti angiogenic 
therapy are highly desirable.
Patient and Methods
The patient, specifically his response to bevacizumab with a follow-up 
of 4 months, was reported previously [6]. After written informed consent 
from the patient, treatment with bevacizumab at 10 mg/kg was adminis-
tered intravenously every 14–21 days on the basis of compassionate use of 
the drug. Radiographic follow-up analyses were performed with 1.5-Tesla 
magnetic resonance imaging (MRI) according to standard procedures. 
The tissue specimen from the surgery before treatment with bevacizumab 
consisted of a 0.4 × 0.2 × 0.01 cm soft, red-brown tissue fragment. At 
 progression after bevacizumab, the tissue comprised multiple beige frag-
ments measuring 8 × 7 × 2 mm in aggregate.
Case Report
Clinical and Radiological Course
A 70-year-old man with a history of a solitary left cerebellar hem-
angioblastoma resected in 1994 was diagnosed with local tumor recur-
rence in 2009 and multiple leptomeningeal cerebral and spinal lesions in 
2010. No other lesions suggestive of VHL disease were found, and no 
germ-line mutation was identified upon analysis of exons 1–3 of the VHL 
gene. After rapid radiological and clinical progression, experimental treat-
ment with bevacizumab was initiated. The clinical course up to 4 months 
after start of treatment was described previously [6]. In brief, upon initia-
tion of bevacizumab treatment, the patient’s gait disorder and perfor-
mance status improved remarkably and the formerly progressive lesions 
on imaging (fig. 1A, B) showed stable disease in the first follow-up after 
2 months. The patient was maintained on bevacizumab, and MRI imaging 
showed sustained stable disease up to 12 months after start of therapy 
(fig. 1C). 3 months later, however, routine MRI scans revealed an in-
tramedullary contrast-enhancing lesion, which showed further progres-
sion in the subsequent follow-up scan (fig. 1D, right). Later, progression of 
the extramedullary, intradural cystic lesions was found near the spinal 
cord at the levels of C7 and T11 (fig. 1D, left). In line with the radiological 
course, ambulation difficulty was documented on examination. Another 
surgery was performed in order to prevent further compression of the 
 spinal cord. Intraoperatively, the lower dorsal lesion appeared super-
ficially infiltrative but exophytic and was completely resected. However, 
the upper lesion was ventrally incorporated in the spinal cord and 
 therefore only biopsy could be safely performed to spare the motor tracts. 
The next follow-up scans showed further tumor progression of the 
spinal  lesions, warranting further treatment with limited evidence-based 
options.
Histologic Analysis
The initial diagnosis of hemangioblastoma World Health Organization 
(WHO) grade I was rendered based on cerebellar lesions, and multilocu-
lar disease was confirmed by a biopsy of the spinal leptomeningeal lesions 
at the levels of T10 and T11.
Before therapy with bevacizumab, the tumor was microscopically 
composed of moderately cellular lobules of densely packed tumor cells 
surrounded by a zone of proliferated capillary-caliber vessels and focal 
Fig. 1. Radiologic course before and after treatment with bevacizumab. 
Spinal (left, A–D) and cranial (right, A–C) MRI showing leptomeningeal 
contrast-enhancing lesions (A, arrows) which progressed over a period of 
4 months (B). Durable stable disease was observed for up to 12 months 
after initial treatment with bevacizumab (C). The pattern of progression 
included progressive cystic leptomeningeal tumor (D, left, white arrow) 
and an intramedullary lesion (D, right, white arrow).
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invasiveness is thought to represent a possible escape mecha-
nism after antiangiogenic therapy [10, 11].
In conclusion, VEGF-targeting antiangiogenic therapy in 
cases of hemangioblastoma may involve VEGF-independent 
angiogenesis via other proangiogenic pathways promoting 
tumor growth and tumor invasiveness. Further investigation is 
needed to evaluate the underlying mechanisms of response and 
escape from antiangiogenic therapy in hemangioblastoma.
stromal fibrosis (fig. 2A, B). Cytoplasmic vacuolation was inconspicuous 
and reticulin staining was sparse. Mitotic activity or necrosis was not 
 observed. Dural tissue was not present in the specimen. Immunohisto-
chemical preparations revealed patchy inhibin a-positive tumor cells 
(fig. 2C). The differential diagnosis of a metastatic renal tumor was ex-
cluded by negative staining for pancytokeratin and renal cell carcinoma 
(RCC) antibody, and glial neoplasms by negative staining for glial fibril-
lary acidic protein (GFAP). The Ki-67 proliferation marker labeled 
around 3% (n = 860 cells) of the tumor cells (fig. 2D).
The biopsy after bevacizumab treatment was performed at the levels 
of C7 and Th3. Tissue specimens consisted of multiple fragments of dura 
infiltrated by tumor. The vessels appeared markedly hyalinized and thick-
ened. Interestingly, the tumor cell density was strikingly decreased after 
treatment with bevacizumab (fig. 2E). The preserved vascular structures 
in relation to relatively reduced numbers of tumor cells were confirmed 
via CD31 staining (fig. 2F). The reticulin scaffolding appeared denser, 
likely reflecting increased vessel-associated reticulin fibers rather than 
stromal cell-associated fibers. Similar to the initial biopsy, there was no 
evidence of mitotic activity or necrosis. Only minimal immunolabeling 
with neuron-specific enolase (NSE; data not shown) and inhibin was seen 
(fig. 2G). Despite the relative paucity of stromal cells, the proliferative 
index was high at 20% (n = 134 cells) (fig. 2H).
Discussion
This is the first study documenting the histologic findings in 
a patient with multifocal hemangioblastoma before and after 
antiangiogenic therapy. Recently, VEGF-based antiangiogenic 
therapy has entered clinical practice in selected cases of 
 hemangioblastoma [6–8]. However, these studies mainly show 
disease stabilization, while radiologic response has been de-
scribed in only 1 case of bevacizumab-treated hemangioblas-
toma [7]. Currently, there are no reports delineating the radio-
logic or histologic patterns of response after therapy. In our 
patient, despite an increased proliferation index, the tumor 
cell density was decreased after anti-VEGF treatment and 
vascular structures appeared predominant. Persistent tumor 
vasculature accompanied with a relatively reduced tumor cell 
density in a tissue sample obtained from a radiologically 
 progressive tumor could be interpreted as a sign of VEGF- 
independent angiogenesis. Escape mechanisms from anti-
angiogenic therapy via up-regulation of non-VEGF proangio-
genic signaling, e.g. via angiopoietins, fibroblast growth  factors, 
or placental growth factor, have been proposed in preclinical 
and clinical models [9].
On the other hand, a diffuse infiltrative pattern of hem-
angioblastoma cells within the adjacent dura was seen after 
therapy. This observation may in part be dependent on the 
 biopsy site and extent of sampling. However, the biopsy site of 
the second intervention was in a region of radiographic pro-
gression and therefore presumably represents bevacizumab-
resistant tumor. Additionally, the radiologic pattern of pro-
gression in this patient with the development of an intramed-
ullary lesion may be interpreted in the context of increased 
invasiveness of the tumor after antiangiogenic therapy. In 
other tumor entities, especially glioblastoma, increased tumor 
Fig. 2. Histologic changes after therapy with bevacizumab. Hematoxylin-
eosin- (A, E), CD31- (B, F), inhibin- (C, G) and Ki-67-stained (D, H) tissue 
specimens at 200 × magnification before (left) and after (right) bevaci-
zumab therapy. The initial biopsy featured a compact mixture of generally 
uniform stromal tumor cells and capillary-caliber vessels (A, B). After 
bevacizumab therapy, the stromal tumor cell density appears markedly 
reduced, while the vessels appear thickened and hyalinized, yet relatively 
preserved (E, F). Inhibin-positive stromal cells are seen in the first biopsy 
(C) and within infiltrated dura in the tissue from the second surgery (G). 
Despite the high cellularity, the Ki-67 staining was low at diagnosis (3%, 
n = 860 cells; D). The proliferative index in the second sample was high 
(20%, n = 134 cells; H).
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